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Abstract
Background: We explored the associations of three variants in the uncoupling protein 2 (UCP2)
gene, one variant in the UCP2-UCP3 intergenic region and five variants in the uncoupling protein 3
(UCP3) gene with obesity and diabetes related traits in subjects with impaired glucose tolerance
participating in Finnish Diabetes Prevention Study. Altogether 507 overweight individuals (body
mass index: 31.2 ± 4.5 kg/m2, age: 55 ± 7 years) for whom DNA was available were randomized to
either an intensified diet and physical activity group or to a conventional care control group.
Methods: We analysed the data from the baseline and annual follow-up visits from years 1, 2 and
3. Measurements of anthropometry, plasma glucose and serum insulin in oral glucose tolerance
test, serum total cholesterol, HDL-cholesterol and triglycerides were included. The median follow-
up time for type 2 diabetes incidence was 7 years. Genetic variants were screened by restriction
fragment length polymorphism or Illumina method.
Results: UCP3 gene variant rs3781907  was associated with increased serum total and LDL-
cholesterol levels, at baseline and during the follow-up period. The same variant was associated
with a higher risk of type 2 diabetes. Variants rs1726745, rs11235972 and rs1800849 in the UCP3
gene associated with serum total and LDL-cholesterol at baseline. Haploblock including variants
rs659366, rs653529, rs15763, and rs1726745 was associated with measures of abdominal obesity
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at baseline and in the longitudinal analysis. The haplotype comprising alleles rs659366-G, rs653529-
A, rs15763-G and  rs1726745-A  was associated with higher waist-to-hip ratio, and haplotype
comprising alleles rs3781907-G, rs11235972-A, and rs1800849-T was associated with increased
serum total and LDL-cholesterol concentrations.
Conclusion: Genetic variation in the UCP2-UCP3 gene cluster may act as a modifier increasing
serum lipid levels and indices of abdominal obesity, and may thereby also contribute to the
metabolic aberrations observed in obesity and type 2 diabetes.
Background
UCP2 is a member of the mitochondrial inner membrane
carrier family that is expressed in a wide variety of tissues,
for example in adipose tissue, skeletal muscle and pancre-
atic islets. The function of UCP2 is tissue-dependent, and
its potential roles include the regulation of fat metabolism
directly and indirectly, e.g. via effects on insulin secretion
[1]. It also has a role in the limitation of reactive oxygen
species (ROS) and macrophage-mediated immunity [2].
Recent studies have established UCP2 as a key component
of beta cell glucose sensing, since it seems to regulate glu-
cose-stimulated insulin secretion [1,3], and is also a criti-
cal link between obesity, beta cell dysfunction and type 2
diabetes (T2DM) [4]. UCP2 and UCP3 genes are located
on chromosome 11q13 adjacent to one another [5,6]. In
a recent meta-analysis of genome-wide linkage studies,
suggestive evidence for chromosome 11q13.3-22.3 was
observed for body mass index (BMI) -defined obesity [7].
There are three common variants in the UCP2 gene, one
located in the promoter region (-866 GA, rs659366), one
is a missense variant in exon 4 (Ala55Val, CT, rs660339),
and one locates in the untranslated exon 8 (45 bp DelIns
in the 3'UTR). Their association with traits related to obes-
ity, energy expenditure or T2DM remains controversial
due to inconsistent findings [8-19]. Studies on rs659366
have demonstrated associations between the A allele and
enhanced adipose tissue mRNA expression and decreased
risk of obesity [17], increased energy expenditure [20],
reduced beta cell function and higher risk of T2DM [14],
lower insulin secretion [15], decreased lipid oxidation
[16], increased preclinical atherosclerosis in women [21],
and increased coronary heart disease risk [18]. Krempler
et al. [14] have shown that the functional rs659366 vari-
ant, located in a multifunctional cis-regulatory site, acts as
a binding site for a pancreatic transcription factor PAX6.
Wang et al. [13] found that the heterozygous combination
of the three variants (-866 GA, Val55Val, DelIns) was asso-
ciated with increased BMI, triglyceride and fasting insulin
levels.
While the UCP2 gene is expressed in almost all tissues,
expression of the UCP3 gene is mostly restricted to skele-
tal muscle and brown adipose tissue. Suggested functions
of UCP3 include regulation of fatty acid metabolism,
redox state, and ROS formation [22,23]. UCP3 seems to
be involved in the protection of mitochondria against
lipotoxicity [24]. The human UCP3 gene gives rise to two
main alternative transcripts, the shorter one having a
polyadenylation site in intron 6, which terminates
approximately 50% of the transcripts. Therefore, human
UCP3 exists as long (UCP3L) and short (UCP3S) forms
[19]. A promoter region variant -55 CT (rs1800849) is
potentially interesting since it is located only 6 bp apart
from the TATA box and 4 bp from a DR1 site, which is a
part of a retinoic acid response element [25]. In Pima
Indians the rs1800849-T  allele increased UCP3 mRNA
expression in skeletal muscle compared with the C allele
[25], and the expression level correlated negatively with
BMI [26]. A direct correlation between sleeping metabolic
rate and 24 h energy expenditure and the expression of
UCP3 mRNA was also found in Pima Indians [26]. More-
over, the rs1800849-T allele was associated with higher
waist-to-hip ratio (WHR) [27], decreased risk of T2DM,
and atherogenic lipid profile [28], but associations with
BMI were controversial [29-32]. No association between
rs1800849 and body weight was seen in several studies
[25,33-36].
The aim of this study was to assess the impact of five pre-
viously unexplored variants in addition to the four above-
mentioned known genetic variants in the UCP2-UCP3
gene cluster, either individually or as haplotypes, on obes-
ity and T2DM related traits. The study subjects with
impaired glucose tolerance (IGT) were prospectively fol-
lowed in the Finnish Diabetes Prevention Study (DPS)
[37,38].
Methods
Subjects and research design
The DPS is a randomised, controlled, multicenter study
carried out in Finland in 1993-2000. The DPS study
design and methods used have been reported in detail
elsewhere [37-39]. The main inclusion criteria were BMI
over 25 kg/m2, age 40 to 64 years, IGT based on the mean
values of two oral glucose tolerance tests (OGTTs). A total
of 522 individuals with IGT were randomised into either
a control group or an intensive, individualised diet and
physical exercise intervention group stratified according
to the clinic, sex, and the mean plasma glucose concentra-BMC Medical Genetics 2009, 10:94 http://www.biomedcentral.com/1471-2350/10/94
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tion two hours after an oral glucose load (7.8 to 9.4 or 9.5
to 11.0 mmol/l). DNA was available from 507 individuals
(166 men and 341 women). Their mean BMI was 31.2 ±
4.5 kg/m2 and age 55.3 ± 7.1 years. At the baseline, 5% of
the individuals were using cholesterol lowering medica-
tion. The study protocol was approved by the Ethics Com-
mittee of the National Public Health Institute in Helsinki,
Finland, and the study participants gave written informed
consent. We certify that all applicable institutional and
governmental regulations concerning the ethical use of
human volunteers were followed during this research.
Measurements
A medical history was taken and a physical examination
done at baseline and at each annual follow-up visit [38].
In this study, measurements from baseline to the 3-year
examination were used, including height, weight, waist
circumference (WC), hip circumference, serum lipid lev-
els, and 2 h OGTT with glucose and insulin levels before
(0 min) and after a 75 g glucose load (120 min) [38].
Plasma glucose was measured at each centre by standard
methods. The serum insulin concentration was measured
in a central laboratory by a radioimmunoassay method
(Pharmacia, Uppsala, Sweden). The intra-assay coefficient
of variation was 5.3% and the interassay coefficient of var-
iation was 7.6%. Homeostasis model for insulin resist-
ance (HOMA-IR) was calculated using the formula:
fasting plasma glucose (mmol/l) × fasting serum insulin
(mU/l)/22.5, and homeostasis model for insulin secre-
tion (HOMA-IS) was calculated as 20 × fasting serum
insulin (mU/l)/(fasting plasma glucose [mmol/l] - 3.5)
[40]. Serum levels of total cholesterol, high-density lipo-
protein (HDL) cholesterol and triglycerides were meas-
ured by enzymatic assay in the central laboratory in
Helsinki. Formula of Friedewald [41] was used to calcu-
late the concentration of low density lipoprotein (LDL)
cholesterol.
DNA analysis
The single nucleotide polymorphisms (SNP) for genotype
analysis were selected from the region spanning the UCP2
and UCP3 genes (~34.4 kb) by using the International
HapMap database and Tagger software [42]http://
www.broad.mit.edu/mpg/tagger/server.html.  Rs660339,
rs659366, and rs1800849 were forced in the selection pro-
cedure. The SNPs covered 86.2% of the genetic informa-
tion of the studied region (r2>0.8). It should be noted that
the DelIns variant of the UCP2 gene is not included in the
database, since it is not a SNP but a 45 bp insertion.
The rs659366 and rs660339 variants of the UCP2 gene and
the rs1800849 variant of the UCP3 gene were screened by
the restriction fragment length polymorphism after diges-
tion with MluI, HincII and HaeIII, respectively, with minor
modifications to previously described methods [9,15,43].
The DelIns variant of the UCP2 gene was analysed by gel
electrophoresis of the PCR-product. The intergenic region
variant rs653529 and four variants locating in the UCP3
gene (rs15763, rs1726745, rs3781907, rs11235972) were
genotyped by using the custom Golden Gate genotyping
reagents and consumables (Illumina Inc, San Diego, CA).
Only 501 (rs1726745) or 502 (rs653529, rs15763,
rs3781907, rs11235972) subjects were successfully geno-
typed by Illumina. For other variants, n = 507.
Statistical analysis
The data were analysed using the SPSS/WIN program ver-
sion 14.0 (SPSS, Chigago, IL, USA). The normality of dis-
tributions of study variables was evaluated with the
Kolmogorov-Smirnov test with Lilliefors' correction, and
appropriate transformation was used when necessary. For
variables with skewed distribution, Kruskal-Wallis test
was used. Univariate analysis of variance was used to com-
pare the effect of the gene variants on continuous varia-
bles. Adjustment for age, gender and BMI was done, when
appropriate. In addition, serum lipoprotein and lipid con-
centrations were adjusted for the use of cholesterol-lower-
ing medication as well. Chi square test was used in
comparison of categorical variables. The relative changes
in HOMA-IS from baseline to three years were calculated
as follows: [(parameter 3-year - parameterbaseline)/parame-
terbaseline] × 100%. Longitudinal changes were examined
using repeated measures of General Linear Model. Homo-
geneity of variances was tested using Levene's test. Cox
regression analysis, adjusted for the study group, baseline
weight, weight change and baseline fasting plasma glu-
cose, was performed to evaluate whether the gene variants
predicted the development of T2DM.
Linkage disequilibrium (LD) statistics were calculated by
Haploview software [44] and haplotype analysis was done
by THESIAS 3.1 [45]http://ecgene.net/genecanvas, which
is based on the stochastic-EM algorithm. Haplotype anal-
yses of the quantitative variables were adjusted for age,
gender and BMI, when appropriate. The survival analysis
for haplotypes was adjusted for the study group, baseline
weight, weight change and baseline fasting plasma glu-
cose.
A p-value < 0.05 was considered statistically significant.
Correction for multiple hypothesis testing was performed
with false discovery rate (FDR) using Q-value 1.0 soft-
ware. 0 was estimated with bootstrap method [46] using
 range from 0 to 0.9 by 0.05. Due to the distribution of
p-values, the  was set to 0 for correcting the results of Cox
regression. Essentially, this is a conservative way of calcu-
lating FDR and thereby produces the estimate implicit in
the Benjamini and Hochberg methodology. In text, q
stands for FDR, and is reported for each p < 0.05 and
should be interpreted as minimum FDR that is incurredBMC Medical Genetics 2009, 10:94 http://www.biomedcentral.com/1471-2350/10/94
Page 4 of 13
(page number not for citation purposes)
when calling that test significant. Data are given as means
± SD, unless otherwise indicated.
Results
Genotype and allele frequencies and LD
The genotype frequencies of the nine gene variants were
consistent with the Hardy-Weinberg equilibrium (p-val-
ues ranging from 0.065 to 0.952), and did not differ
between the study groups. Location of the variants in the
UCP2 and UCP3 genes and their minor allele frequencies
and LD statistics (D' and r2) are presented in Figure 1 and
Table 1. D' values were between 0.053 and 1.0, whereas r2
varied from 0.002 to 0.979. Although variants rs11235972
and rs1800849 were in strong linkage disequilibrium (D'
= 1.0 and r2 = 0.979), no completely redundant variants
were observed; thus all nine variants were included in sub-
sequent association analysis. Based on solid spine of LD,
haplotype analysis was done separately for three haplo-
type blocks, block 1 including DelIns and rs660339 vari-
ants of the UCP2 gene, block 2 including rs659366,
rs653529, rs15763 and rs1726745 of the UCP2 and UCP3
genes, and block 3 covering variants rs3781907,
rs11235972 and rs1800849 of the UCP3 gene.
Baseline characteristics of subjects
No significant differences were observed among the geno-
types regarding body weight, BMI, fasting and 2-h insulin
levels, HOMA-IR or HOMA-IS. Fasting and 2-h glucose
levels differed among the rs660339 genotypes (p/q 0.006/
0.006 and 0.025/0.010, respectively), and among the
rs659366 genotypes (p/q 0.007/0.006 and 0.025/0.010,
respectively). Specifically, the rs660339-CC and rs659366-
AA homozygotes had the highest fasting glucose concen-
trations and the rs660339-CC and rs659366-GG homozy-
gotes had the highest 2-h glucose concentrations. In
addition, rs653529 associated with 2-h glucose level, so
that the individuals with AA-genotype had the highest val-
ues (p/q 0.028/0.010), but the associations with glucose
were not dependent on the allele dosage.
Four gene variants in the haploblock 2 associated with
indices of abdominal obesity, namely WC, WHR and
waist-to-height ratio (WHtR). Rs659366, rs653529,
rs15763 and rs1726745 associated with WHR at baseline
(p/q 0.048/0.014, 0.009/0.006, 0.018/0.010 and 0.031/
0.010, respectively), as subjects with rs659366-AA,
rs653529-GG, rs15763-AA and rs1726745-GG genotypes
had the lowest WHR (Table 2). Although less consistent,
associations were also seen between these variants and
WC and WHtR. WC was associated with rs659366,
rs653529 and rs1726745, whereas WHtR was associated
with rs653529, rs15763 and rs1726745 (Table 2). Also the
DelIns variation in UCP2 associated with WHR, subjects
with the DelDel genotype having the highest WHR at base-
line (p/q 0.017/0.256).
Rs1726745, rs3781907, rs11235972 and rs1800849 were
associated with serum total cholesterol and LDL-choles-
terol levels. Subjects with rs1726745-GG, rs3781907-GG,
rs11235972-AA  and  rs1800849-TT  genotypes had the
highest serum total cholesterol concentrations among the
variants (p/q 0.022/0.010, 0.005/0.006, 0.032/0.010 and
0.050/0.014, respectively), as well as serum LDL-choles-
terol (p/q  0.005/0.006, 0.004/0.006, 0.045/0.014 and
0.071/0.018, respectively). Moreover, the total choles-
terol-to-HDL-cholesterol ratio was highest for the subjects
with rs3781907-GG genotype (p/q 0.045/0.013). Baseline
characteristics of the DPS subjects according to rs3781907
are presented in the Table 3. Regarding rs3781907 and
rs11235972, the results on lipids and lipoproteins
remained unchanged, if the individuals using cholesterol
lowering medication (n = 25) were excluded from the
analyses. Regarding rs1726745, and rs1800849, the results
were statistically significant only for rs1726745 associa-
Table 1: Pairwise linkage disequilibrium, presented as D' and r2 values, among the nine variants in UCP2 and UCP3 genes (haploblocks 
are shown bolded)
SNP ID D'
DelIns rs660339 rs659366 rs653529 rs15763 rs1726745 rs3781907 rs11235972 rs1800849
r2 DelIns
(0.297)
0.977 0.684 0.630 0.906 0.402 0.829 0.856 0.857
rs660339 CT (0.470) 0.451 0.985 0.912 0.862 0.548 0.282 0.056 0.053
rs659366 GA (0.403) 0.292 0.736 0.952 0.867 0.844 0.218 0.133 0.134
rs653529 AG (0.415) 0.236 0.663 0.863 0.902 0.805 0.243 0.119 0.125
rs15763 GA (0.218) 0.542 0.232 0.309 0.318 1.0 0.871 0.934 0.933
rs1726745 GA (0.403) 0.046 0.181 0.325 0.311 0.188 0.756 0.948 0.940
rs3781907 AG (0.327) 0.140 0.034 0.016 0.020 0.102 0.189 0.804 0.807
rs11235972 GA (0.371) 0.181 0.002 0.015 0.012 0.142 0.358 0.535 1.0
rs1800849 CT (0.377) 0.185 0.002 0.016 0.013 0.145 0.360 0.527 0.979
Major/minor alleles, and the frequencies of the minor alleles of the corresponding variants are indicated next to each variant identification numberBMC Medical Genetics 2009, 10:94 http://www.biomedcentral.com/1471-2350/10/94
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tion with LDL-cholesterol, if the individuals using choles-
terol lowering medication were excluded.
The 3-year changes
Longitudinal analysis of WHR showed that subjects with
rs653529-GG, rs15763-AA and rs1726745-GG genotypes
had the lowest WHR throughout the 3-year follow-up (p/
q  0.025/0.030, 0.039/0.030 and 0.035/0.030, respec-
tively) (Figure 2). Longitudinal analyses of WC and WHtR
showed similar results, with WC being associated with
rs15763  (p/q  0.030/0.030) and WHtR associating with
rs15763  and  rs1726745  (p/q  0.009/0.030, 0.040/0.030,
respectively).
Longitudinal changes in serum cholesterol levels were
associated with rs3781907-AA genotype having the lowest
total cholesterol (p/q 0.020/0.030) and LDL-cholesterol
(p/q  0.010/0.030) throughout the years 0-3 (Figure 3).
Subjects with rs3781907-AA genotypes also had the lowest
serum triglyceride levels, but this was seen only in the con-
trol group (p/q 0.039/0.030). HDL-cholesterol level was
lowest among the subjects with rs3781907-GG genotype
in the intervention group (p/q 0.041/0.030). Furthermore,
the total cholesterol-to-HDL cholesterol ratio was highest
among subjects with the rs3781907-GG genotype in the
entire DPS (p/q 0.015/0.030). All these results remained
significant if the individuals using cholesterol lowering
medication were excluded.
The 3-year change in HOMA-IS was associated similarly
with all three UCP2 variants (DelIns, rs660339, rs659366),
the intergenic region variant rs653529 and UCP3 variant
rs15763, showing increased values for wild-type subjects,
intermediate for heterozygous and the lowest values for
Schematic representation of the UCP2 and UCP3 genes indicating the locations of the analysed variants Figure 1
Schematic representation of the UCP2 and UCP3 genes indicating the locations of the analysed variants. Grey 
boxes, coding region; white boxes, UTR; dotted line, intergenic region of ~17 kb.
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Table 2: Associations of representative SNPs in the UCP2-UCP3 gene region with indices of abdominal obesity at the baseline
Genotype
SNP Obesity index Homozygous for the common allele Heterozygous Homozygous for the rare allele pa q
rs659366 WC, cm 102 ± 11 101 ± 11 100 ± 11 0.033 0.010
WHR 0.93 ± 0.07 0.92 ± 0.07 0.91 ± 0.08 0.048 0.014
WHtR 0.61 ± 0.06 0.61 ± 0.06 0.61 ± 0.07 0.119 0.027
rs653529 WC, cm 102 ± 11 101 ± 11 100 ± 11 0.011 0.007
WHR 0.93 ± 0.07 0.92 ± 0.07 0.91 ± 0.08 0.009 0.006
WHtR 0.61 ± 0.06 0.61 ± 0.06 0.60 ± 0.07 0.022 0.010
rs15763 WC, cm 102 ± 11 100 ± 10 100 ± 12 0.075 0.019
WHR 0.92 ± 0.07 0.92 ± 0.07 0.90 ± 0.07 0.018 0.010
WHtR 0.61 ± 0.07 0.60 ± 0.06 0.60 ± 0.07 0.024 0.010
rs1726745 WC, cm 100 ± 11 102 ± 11 102 ± 11 0.008 0.006
WHR 0.91 ± 0.08 0.92 ± 0.07 0.93 ± 0.07 0.031 0.010
WHtR 0.60 ± 0.06 0.62 ± 0.06 0.61 ± 0.07 0.003 0.006
Data are means ± SD
aUnivariate ANOVA, adjusted for age, gender, BMI
WC, waist circumference; WHR, waist-to-hip ratio; WHtR, waist-to-height ratioBMC Medical Genetics 2009, 10:94 http://www.biomedcentral.com/1471-2350/10/94
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homozygous subjects (p/q  0.004/0.304, 0.016/0.325,
0.037/0.325, 0.018/0.325 and 0.016/0.325, respectively),
whereas no association with other four UCP3 variants was
found.
Haplotype analysis
In order to confirm the associations with serum lipids and
WHR, haplotype analysis was performed separately for
blocks 1, 2, and 3. Only the haplotypes with frequency 
0.05 were included in the analysis; thus, block 1 consisted
of 3 haplotypes (DelC, InsT, and DelT), block 2 of 4 hap-
lotypes (GAGA, GAGG, AGAG, and AGGG) and block 3 of
3 different haplotypes (AGC, GAT, and AAT) (Table 4).
In block 2 the haplotype AGAG showed lower WHR at
baseline when compared with the reference haplotype
GAGA (p = 0.050). In block 3 the haplotype GAT had
higher serum total cholesterol (p = 0.006) and LDL-cho-
lesterol (p = 0.024) at baseline when compared with the
reference haplotype AGC. Moreover, the haplotype AAT
showed a greater decrease (0-3 years) in LDL-cholesterol
level compared with the reference haplotype AGC during
the 3-year follow-up (p = 0.037). No associations were
seen for the haplotypes in the haploblock 1.
Conversion to T2DM
During a median follow-up of seven years 185 individuals
(75 in the intervention group and 110 in the control
group) developed T2DM. The subjects with the
rs3781907-G allele were at a higher risk for T2DM when
compared with subjects with AA genotype, with hazard
ratio (HR) of 1.48 (95%CI 1.09-2.00), p/q 0.011/0.100.
We also analysed the genotype × study group interaction
for the diabetes conversion, but it was not statistically sig-
nificant (p = 0.447). The percentage of subjects with AA
genotype converting to T2DM was 33%, whereas it was
38% and 48% for the subjects with AG and GG genotypes,
respectively (p/q 0.039/0.394) (Table 3). The percentages
of converters were similar for both study groups, with GG
genotype showing the highest and AA genotype showing
the lowest percentages of converters.
Surprisingly, subjects in the intervention group carrying
the UCP2 InsIns genotype were at a higher risk compared
with subjects with Del allele, with HR 2.53 (95%CI 1.11-
5.73), p/q  0.027/0.243. Such a risk increment was not
seen in the control group, nor in the entire DPS. No gen-
otype × study group interaction was seen here either.
The conversion to T2DM during the follow-up did not dif-
fer significantly among the other gene variants. In the hap-
lotype analysis, none of the haplotypes studied were
associated with an increased risk of T2DM.
Discussion
In the present study we evaluated whether the UCP2 and
UCP3  genes act as modifiers for obesity and diabetes
related risk factors. This study provides new evidence con-
cerning associations between genetic variations in the
UCP2 and UCP3 genes and serum lipid concentrations as
well as indices of abdominal obesity, both being charac-
teristics of the metabolic syndrome. Previous studies have
explored effects of these genes on various traits in several
populations, with inconsistent results concerning associa-
Table 3: Baseline characteristics and conversion to type 2 diabetes (T2DM) according to the genotypes of SNP rs3781907 at UCP3 
gene
Genotype
AA AG GG pb q
n (M/F)a 221 (73/148) 233 (79/154) 48 (13/35) 0.645 0.714
Age (years) 56 ± 7 55 ± 7 53 ± 7 0.077c 0.421
Weight (kg) 86.3 ± 14.6 85.8 ± 13.5 87.3 ± 15.9 0.878 0.924
BMI (kg/m2) 31.3 ± 4.8 31.1 ± 4.2 31.6 ± 5.2 0.991 0.954
Waist-to-hip ratio 0.92 ± 0.07 0.92 ± 0.07 0.93 ± 0.08 0.583 0.067
Fasting plasma glucose (mmol/l) 6.2 ± 0.8 6.1 ± 0.7 6.2 ± 0.7 0.295 0.047
Fasting serum insulin (pmol/l) 85 ± 40 92 ± 51 86 ± 30 0.665c 0.070
Serum total cholesterol (mmol/l) 5.5 ± 0.9 5.7 ± 0.9 5.9 ± 1.0 0.005 0.006
Serum LDL-cholesterol (mmol/l) 3.5 ± 0.8 3.7 ± 0.8 3.9 ± 1.0 0.004 0.006
Serum HDL-cholesterol (mmol/l) 1.22 ± 0.29 1.22 ± 0.30 1.17 ± 0.25 0.834 0.081
Serum triglycerides (mmol/l) 1.69 ± 0.73 1.74 ± 0.83 1.81 ± 0.70 0.558 0.066
Total cholesterol-to-HDL-cholesterol ratio 4.73 ± 1.22 4.90 ± 1.26 5.15 ± 1.15 0.045 0.013
Converters to T2DM (n/%)a 72/33% 89/38% 23/48% 0.039 0.394
Data are means ± SD
a2 test
b Univariate ANOVA, adjusted for age and sex (anthropometric measurements), for age, sex and BMI (glucose, insulin), or for age, sex, BMI, and the 
use of cholesterol lowering medication (lipids)
c Kruskal-Wallis testBMC Medical Genetics 2009, 10:94 http://www.biomedcentral.com/1471-2350/10/94
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Waist-to-hip ratio from baseline to year 3 according to rs653529 (a), rs15763 (b), and rs1726745 (c) variants, p/q 0.025/0.030,  0.039/0.030 and 0.035/0.030, respectively Figure 2
Waist-to-hip ratio from baseline to year 3 according to rs653529 (a), rs15763 (b), and rs1726745 (c) variants, p/q 
0.025/0.030, 0.039/0.030 and 0.035/0.030, respectively. Data are mean ± SEM.
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Serum total cholesterol (a) and LDL-cholesterol (b) levels, from baseline to year 3, according to rs3781907 variant of the UCP3  gene, p/q 0.020/0.030 and 0.010/0.030, respectively Figure 3
Serum total cholesterol (a) and LDL-cholesterol (b) levels, from baseline to year 3, according to rs3781907 var-
iant of the UCP3 gene, p/q 0.020/0.030 and 0.010/0.030, respectively. Data are mean ± SEM.
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Table 4: Frequencies and associations of the major haplotypes (frequency  0.05) of three haploblocks in the UCP2-UCP3 gene region
Haploblock Marker Frequency Association
Block 1 DelIns rs660339
Del C 0.519a NS
Ins T 0.300 NS
Del T 0.177 NS
Block 2 rs659366 rs653529 rs15763 rs1726745
GA GA0.359a NS
GA GG0.203 NS
AG AG0.202  WHR, p = 0.050b
AG GG0.175 NS
Block 3 rs3781907 rs11235972 rs1800849
AG C 0.584a NS
GA T 0.288  cholesterol, p = 0.006c
 LDL, p = 0.024c
AA T 0.084 LDL, p = 0.037c
a The most frequent haplotype is the reference, with which the others are compared
b Adjusted for age and gender
c Adjusted for age, gender and BMI
, higher in comparison with the reference haplotype; , lower in comparison with the reference haplotype
Table 5: Associations of UCP2 and UCP3 gene variants with waist-to-hip ratio (WHR) and serum lipid concentrations in previous 
studies
Ref. Subjects
(number, ethnicity)
Variant Risk allele Association
WHR [43] 710, South Indian
450, Caucasoid
UCP3: rs1800849 T Higher WHR
[27] 162, Caucasoid UCP3: rs1800849 T Higher WHR
[34] 460, Asian UCP3: haplotype
including rs1800849
C in haplotype CGTACC Higher WHR
Lipids [28] 1175, Caucasoid UCP3: rs1800849 T Higher total
and LDL-cholesterol conc.
[13] 796, several UCP2: rs659366
UCP2: rs660339
UCP2: Del/Ins
Heterozygous genotype combination GTI/
ATD
Higher triglyceride
concentration
[56] 681, Caucasoid UCP2: rs659366 A Higher
triglyceride, total
and LDL-cholesterol conc.
[55] 658, Asian UCP2: rs659366
UCP2: rs660339
A
T
Lower HDL-cholesterol concentration
[32] 282, Japanese UCP3: rs1800849 C Lower HDL-cholesterol concentrationBMC Medical Genetics 2009, 10:94 http://www.biomedcentral.com/1471-2350/10/94
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tions with lipid levels and WHR/abdominal obesity
(Table 5). The study subjects in the DPS were overweight
with IGT, and thus at a high risk to develop T2DM. The
advantages of this study population are i) homogenous,
carefully selected and phenotyped subjects, ii) prospective
study design with extensive longitudinal follow-up data
on key variables, iii) confirmation of new T2DM diagno-
sis based upon two subsequent OGTTs, and iv) Finnish
population with only few founding members and thus
genetically relatively homogeneous. On the other hand,
one drawback for genetic analyses in the DPS is the lim-
ited power due to relatively small sample-size, particularly
if the analyses are carried out in smaller sub-groups. In
this study, stratification to different groups was unneces-
sary, since the associations with WHR and lipid levels
were observed in the entire DPS study population.
To our knowledge, this is the first study exploring effects
of the gene variants rs653529, rs15763,  rs1726745,
rs3781907  and  rs11235972  on several metabolic traits.
Interestingly, subjects with rs3781907-G  allele experi-
enced a higher risk of T2DM and dyslipidemia compared
with subjects homozygous for the common allele. The
conversion to T2DM and serum levels of total cholesterol,
LDL-cholesterol and total cholesterol-to-HDL-cholesterol
ratio were modified by the dosage of rs3781907-G allele.
The UCP3 promoter variant rs1800849, which is located
in the same haploblock and is in LD with rs3781907, has
been previously shown to be associated with an increased
[47] or decreased [28] risk of T2DM, increased skeletal
muscle UCP3 mRNA expression [25], higher total, LDL-
[28] and HDL-cholesterol concentrations [32], higher
[29] or lower BMI [30-32], higher WHR [27,43] and
higher fat mass and lean mass [48]. In this study
rs1800849  was associated with higher total cholesterol
and LDL-cholesterol concentration at baseline, both as
alleles and also as a member of the haploblock 3, in line
with findings from earlier studies [28]. Interestingly, all
the haploblock 3 variants were associated with total and
LDL-cholesterol at the baseline, although the most con-
sistent association with various serum lipoprotein and
lipid concentrations at baseline and longitudinally was
seen for rs3781907 that was also a risk factor for conver-
sion to T2DM. FDR was low for these associations, which
further provides support for our findings. However, as no
previous studies with this variant exist, a confirmation of
the present results is needed in other populations.
Although none of the gene variants were associated with
weight or BMI, variants in the haploblock 2 associated
with several indices of abdominal obesity at baseline
(rs659366, rs653529, rs15763, rs1726745) and longitudi-
nally (rs653529, rs15763, rs1726745). Although waist cir-
cumference and BMI are strongly correlated [49], WC,
WHR and WHtR are all independent obesity-related pre-
dictors of cardiovascular risk independent of BMI [50],
and together with serum lipid concentrations they are
simple clinical surrogate markers of excess visceral/ectopic
fat [49]. In this study the genetic variation in UCP2-UCP3
gene cluster seemed to be also associated with both serum
lipids and indices of abdominal obesity as well. The sin-
gle-marker associations were mostly haploblock specific,
so that the markers from haploblock 2 were associated
with central obesity indices, whereas the markers from the
haploblock 3 were associated with serum cholesterol con-
centrations. The results of haplotype analyses were in line
with the results of single marker analyses, but they did not
reveal a haplotype that would explain the associations
substantially better than the individual markers. We con-
clude that rs1726745 explains most of the associations
(both baseline and longitudinal) seen in haploblock 2
with central obesity, and rs3781907 explains most of the
associations seen in haploblock 3 with total and LDL-cho-
lesterol concentrations. However, it is difficult to suggest
whether the causative variant truly is one of the studied
markers or simply a SNP that is in complete disequilib-
rium with them.
As for the functional UCP2  promoter variant -866 GA
(rs659366), previous studies have found that it is associ-
ated with a reduced prevalence of obesity [17], reduced
risk of coronary artery disease [51], reduced [52] or
increased [14] risk of T2DM, lower insulin secretion
[15,53], reduced insulin sensitivity [54], a decreased [13]
or increased [17]UCP2  mRNA level in adipose tissue,
higher oxidative stress and risk of coronary heart disease
[18], decreased HDL-cholesterol [55], and increased
serum triglyceride, total cholesterol and LDL-cholesterol
levels [56]. In our study, the subjects with the rs659366-A
allele had lower WC and WHR at baseline, compared with
subjects with G allele, both individually as well as a mem-
ber of haploblock 2. Also the insulin secretion, measured
by HOMA-IS, seemed to be decreased most in the subjects
with  rs659366-A  allele during the 3-year follow-up,
although no differences were seen at the baseline. These
findings are in line with previous findings [15,17,53].
FDR was low for the associations with abdominal obesity
indices thus supporting it, but high for the associations
with HOMA-IS, which of course weakens the strength of
this finding.
UCP2 has been said to act as adiposity angel and diabetes
devil [57], whereas increased expression of UCP3 has
been suggested to be associated with weight loss success
[58]. The promoter area variant alleles in UCP2
(rs659366-A) and in UCP3 (rs1800849-T) have been
shown to increase gene expression, and thus these alleles
might protect against obesity. In our study the rs659366-A
allele were associated with lower WHR and WC at base-
line, in line with findings by Esterbauer et al. [17]. How-BMC Medical Genetics 2009, 10:94 http://www.biomedcentral.com/1471-2350/10/94
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ever, no association between rs1800849 and obesity was
seen in this study. Neither were the promoter area variants
associated with risk of T2DM. This could be due to the rel-
atively small study population, and also the genetic
'makeup' varies from one population to another. Further-
more, as the mean BMI of the study population was 31.2
kg/m2, the 'obese character' may also have masked the
effects of these genetic variants, which may explain the
lack of association with obesity.
Conclusion
In summary, several novel findings were detected and
they need to be confirmed. The subjects with the
rs3781907-G allele had higher levels of serum total and
LDL-cholesterol concentrations at baseline and at longitu-
dinal follow-up, and a higher risk of T2DM, when com-
pared with the subjects with A-allele. The subjects with
rs1726745-G, rs11235972-A and rs1800849-T alleles had
also higher serum total and LDL-cholesterol concentra-
tions compared with those carrying the more common
alleles. Several variants (rs659366-AA, rs653529-GG,
rs15763-AA  and  rs1726745-GG) were associated with
lower abdominal obesity indices, at baseline and longitu-
dinally.
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